Dec 6 (Reuters) - AbbVie (ABBV.N) said on Wednesday it would buy Cerevel Therapeutics (CERE.O), a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.